11 citations
,
April 2018 in “Journal of Dermatology” In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.
27 citations
,
March 2017 in “Current Clinical Pharmacology” In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.
27 citations
,
February 2017 in “Biomedicine & Pharmacotherapy” This study found that white wax and its extract may promote hair growth in a mouse model of androgenetic alopecia by inhibiting 5α-reductase activity and increasing cell proliferation, with efficacy surpassing finasteride.
32 citations
,
July 2016 in “PubMed” This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.
6 citations
,
February 2016 in “Journal of Microencapsulation” This study found that injectable finasteride microspheres provided a sustained drug release with a minimal initial burst in albino rabbits compared to oral suspension.
33 citations
,
January 2016 in “Skin appendage disorders” This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.
33 citations
,
January 2016 in “Indian Journal of Dermatology, Venereology and Leprology” This review discusses the use of finasteride for androgenetic alopecia and highlights that while it is considered safe, there is concern regarding its sexual side effects, which reverse upon discontinuation.
35 citations
,
January 2014 in “Postepy Dermatologii I Alergologii” This study found that increased dihydrotestosterone levels were observed in both androgenetic alopecia patients and controls, suggesting that follicle sensitivity to DHT may be more critical than DHT levels for alopecia development.
2152 citations
,
November 2013 in “Urologia Internationalis” This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.
52 citations
,
November 2013 in “European Journal of Pharmaceutical Sciences” This study examined different polymersome systems for topical finasteride delivery and found that chitosan-decorated C7 polymersomes may enhance skin retention and provide controlled drug release compared to non-decorated systems in laboratory settings.
218 citations
,
December 2011 in “Advances in Urology” This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.
41 citations
,
October 2011 in “Journal of Dermatology” This study observed that long-term use of finasteride in Japanese men with androgenetic alopecia was associated with progressive hair regrowth in 87.1% of participants without significant safety concerns.
44 citations
,
October 2010 in “BJUI” This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.
152 citations
,
October 2010 in “Archives of Dermatology” This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
37 citations
,
May 2007 in “International Journal of Pharmaceutics” The study concluded that poly(propylene carbonate maleate) microspheres effectively encapsulated finasteride, achieving a biphasic release with prolonged drug release over 5-6 weeks in vitro.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.
22 citations
,
July 2003 in “PubMed” This study reported that finasteride 1 mg significantly improved hair growth in men aged 41 to 60 with predominantly vertex male pattern hair loss over 24 months compared to placebo.
20 citations
,
April 2002 in “PubMed” This study found that long-term treatment with finasteride 1 mg/day significantly improved scalp hair growth and was well tolerated in men with androgenetic alopecia over five years compared to placebo.
116 citations
,
September 2001 in “Journal of The American Academy of Dermatology” This study suggests that miniaturization in pattern hair loss may occur abruptly and can be reversed with treatment, as supported by histologic evidence in finasteride-responsive patients.
138 citations
,
March 2001 in “Clinics in Dermatology” This review discusses the relationship between perceived stress and hair loss or graying, exploring hair follicles as a model system but reports no new clinical results.
65 citations
,
October 1999 in “Journal of The American Academy of Dermatology” In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.
581 citations
,
October 1998 in “Journal of The American Academy of Dermatology” In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.
179 citations
,
September 1998 in “BMJ” This article reviews the pathogenesis, genetic basis, and recent treatment breakthroughs for androgenetic alopecia but reports no new clinical findings.
124 citations
,
January 1996 in “Dermatology” This article reviews the biochemical properties of 5 alpha-reductase isoforms and highlights the limited dermatological use of inhibitors like finasteride, especially for type 1 isozyme-targeting agents, while suggesting further clinical exploration.
1040 citations
,
October 1992 in “The New England Journal of Medicine” In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.
